Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J; NASH CRN Research Group.

Contemp Clin Trials. 2009 Jan;30(1):88-96. doi: 10.1016/j.cct.2008.09.003. Epub 2008 Sep 10.

PMID:
18804555
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.

Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group.

Contemp Clin Trials. 2010 Jan;31(1):62-70. doi: 10.1016/j.cct.2009.09.001. Epub 2009 Sep 15.

PMID:
19761871
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN.

N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28.

PMID:
20427778
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN).

Aliment Pharmacol Ther. 2013 Jul;38(2):134-43. doi: 10.1111/apt.12352. Epub 2013 May 29.

PMID:
23718573
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.

Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS.

Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15.

PMID:
15625656
[PubMed - indexed for MEDLINE]
6.

Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.

Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM, McCullough AJ, Bass NM, Diehl AM, Unalp-Arida A, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network.

Hepatology. 2012 Oct;56(4):1311-8. doi: 10.1002/hep.25805. Epub 2012 Aug 21.

PMID:
22532269
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Vitamin E and nonalcoholic fatty liver disease.

Pacana T, Sanyal AJ.

Curr Opin Clin Nutr Metab Care. 2012 Nov;15(6):641-8. doi: 10.1097/MCO.0b013e328357f747. Review.

PMID:
23075940
[PubMed - indexed for MEDLINE]
8.

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network.

JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520.

PMID:
21521847
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.

Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N.

Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380. Review.

PMID:
22059955
[PubMed - indexed for MEDLINE]
Free Article
10.

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.

Boettcher E, Csako G, Pucino F, Wesley R, Loomba R.

Aliment Pharmacol Ther. 2012 Jan;35(1):66-75. doi: 10.1111/j.1365-2036.2011.04912.x. Epub 2011 Nov 4.

PMID:
22050199
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K.

N Engl J Med. 2006 Nov 30;355(22):2297-307.

PMID:
17135584
[PubMed - indexed for MEDLINE]
Free Article
12.

[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].

Heebøll S, Kazankov K, Poulsen MK, Vilstrup H, Grønbæk H.

Ugeskr Laeger. 2012 Feb 20;174(8):488-90. Danish.

PMID:
22348670
[PubMed - indexed for MEDLINE]
13.

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.

Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K.

Hepatology. 2009 Oct;50(4):1087-93. doi: 10.1002/hep.23116.

PMID:
19670459
[PubMed - indexed for MEDLINE]
14.

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.

Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S.

Am J Gastroenterol. 2003 Nov;98(11):2485-90.

PMID:
14638353
[PubMed - indexed for MEDLINE]
15.

Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.

Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005166. Review.

PMID:
17253544
[PubMed - indexed for MEDLINE]
16.

Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Lomonaco R, Sunny NE, Bril F, Cusi K.

Drugs. 2013 Jan;73(1):1-14. doi: 10.1007/s40265-012-0004-0. Review.

PMID:
23329465
[PubMed - indexed for MEDLINE]
17.

[Steatosis and steatohepatitis in diabetic patient].

Hůlek P, Dresslerová I.

Vnitr Lek. 2011 Apr;57(4):364-7. Review. Czech.

PMID:
21612059
[PubMed - indexed for MEDLINE]
18.

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.

Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M; EPE-A Study Group.

Gastroenterology. 2014 Aug;147(2):377-84.e1. doi: 10.1053/j.gastro.2014.04.046. Epub 2014 May 9.

PMID:
24818764
[PubMed - indexed for MEDLINE]
19.

Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.

Zhang W, Wu R, Zhang F, Xu Y, Liu B, Yang Y, Zhou H, Wang L, Wan K, Xiao X, Zhang X.

Clin Exp Pharmacol Physiol. 2012 Dec;39(12):1026-33. doi: 10.1111/1440-1681.12020.

PMID:
23127227
[PubMed - indexed for MEDLINE]
20.

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H.

Cochrane Database Syst Rev. 2013 Dec 27;12:CD008623. doi: 10.1002/14651858.CD008623.pub2. Review.

PMID:
24374462
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk